{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:22:48Z","timestamp":1779895368748,"version":"3.53.1"},"reference-count":23,"publisher":"The Pediatric Pharmacy Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10,1]]},"abstract":"<jats:p>A former 34-week-old female infant with Down syndrome underwent surgical correction of a congenital heart defect at 5 months of age. Her postoperative course was complicated by severe pulmonary hypertension and junctional ectopic tachycardia. Following treatment with amiodarone infusion, she developed laboratory indices of acute liver injury. At their peak, liver transaminase levels were 19 to 35 times greater than the upper limit of normal. Transaminitis was accompanied by coagulopathy, hyperammonemia, and high serum lactate and lipid levels. Hepatic laboratory abnormalities began to resolve within 48 hr of stopping amiodarone infusion. Heart rate control was achieved concurrently with discovery of laboratory test result abnormalities, and no further antiarrhythmic therapy was required. The intravenous formulation of amiodarone contains the diluent polysorbate 80, which may have hepatotoxic effects. Specifically, animal studies suggest that polysorbate 80 may destabilize cell membranes and predispose to fatty change within liver architecture. Polysorbate was implicated in infant fatalities from E-ferol use in the 1980s. This case illustrates a possible adverse event by the Naranjo probability scale. Given the extent of clinically apparent hepatic injury, this patient was not rechallenged with amiodarone during the remainder of her hospitalization. With amiodarone now used as first-line pharmacologic therapy for critical tachyarrhythmia in this population, the number of children exposed to this drug should be expected to increase. Laboratory indices of liver function should be evaluated at initiation of amiodarone therapy, as well as frequently throughout duration of therapy. Consideration should be given to polysorbate-free formulation of intravenous amiodarone for use in the cohort with congenital cardiac disease.<\/jats:p>","DOI":"10.5863\/1551-6776-17.2.189","type":"journal-article","created":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T21:46:21Z","timestamp":1349819181000},"page":"189-195","source":"Crossref","is-referenced-by-count":4,"title":["Hepatotoxicity After Continuous Amiodarone Infusion in a Postoperative Cardiac Infant"],"prefix":"10.5863","volume":"17","author":[{"given":"Jennifer S.","family":"Kicker","sequence":"first","affiliation":[{"name":"Division of Pediatriac Critical Care, Department of Pediatrics, University of Virginia Children's Hospital, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Haizlip","sequence":"additional","affiliation":[{"name":"Division of Pediatriac Critical Care, Department of Pediatrics, University of Virginia Children's Hospital, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcia L.","family":"Buck","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Services, University of Virginia Children's Hospital, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"5","key":"2020102715524706600_i1551-6776-17-2-189-b01","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00392-004-0067-3","article-title":"Postoperative junctional ectopic tachycardia (JET)","volume":"93","author":"Haas","year":"2004","journal-title":"Z Kardiol"},{"issue":"5","key":"2020102715524706600_i1551-6776-17-2-189-b02","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/0735-1097(95)00591-9","article-title":"Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol","volume":"27","author":"Perry","year":"1996","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2020102715524706600_i1551-6776-17-2-189-b03","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/hrt.59.6.690","article-title":"Acute hepatitis after parental amiodarone administration","volume":"59","author":"Pye","year":"1988","journal-title":"Br Heart J"},{"issue":"3","key":"2020102715524706600_i1551-6776-17-2-189-b04","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0002-9343(02)01149-X","article-title":"Acute hepatitis induced by parenteral amiodarone","volume":"113","author":"Gregory","year":"2002","journal-title":"Am J Med"},{"issue":"9","key":"2020102715524706600_i1551-6776-17-2-189-b05","doi-asserted-by":"crossref","first-page":"1082.e1","DOI":"10.1016\/j.ajem.2007.02.045","article-title":"Acute toxic hepatitis after amiodarone intravenous loading","volume":"25","author":"Rizzioli","year":"2007","journal-title":"Am J Emerg Med"},{"issue":"1","key":"2020102715524706600_i1551-6776-17-2-189-b06","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.CCM.0000151048.72393.44","article-title":"Hepatotoxicity during rapid intravenous loading with amiodarone: description of three cases and review of the literature","volume":"33","year":"2005","journal-title":"Crit Care Med"},{"issue":"2","key":"2020102715524706600_i1551-6776-17-2-189-b07","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"2020102715524706600_i1551-6776-17-2-189-b08","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1161\/01.CIR.77.1.200","article-title":"The antiarrhythmic efficacy of amiodarone and desethylamiodarone, alone and in combination, in dogs with acute myocardial infarction","volume":"77","author":"Nattel","year":"1988","journal-title":"Circulation"},{"issue":"9","key":"2020102715524706600_i1551-6776-17-2-189-b09","doi-asserted-by":"crossref","first-page":"689","DOI":"10.7326\/0003-4819-122-9-199505010-00008","article-title":"Amiodarone: reevaluation of an old drug","volume":"122","author":"Podrid","year":"1995","journal-title":"Ann Intern Med"},{"issue":"3","key":"2020102715524706600_i1551-6776-17-2-189-b10","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/157016108784912019","article-title":"Amiodarone hepatotoxicity","volume":"6","author":"Babatin","year":"2008","journal-title":"Curr Vasc Pharmacol"},{"key":"2020102715524706600_i1551-6776-17-2-189-b11","unstructured":"US Food and Drug Administration. Guidance for Industry, Drug-Induced Liver Injury: Premarketing Clinical Evaluation: 2009. Silver Spring, MD: US Department of Health and Human Services Food and Drug Administration ; 75 Federal Register 14602\u201314603;2009."},{"issue":"4","key":"2020102715524706600_i1551-6776-17-2-189-b12","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/gut.34.4.565","article-title":"Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle?","volume":"34","author":"Rhodes","year":"1993","journal-title":"Gut"},{"key":"2020102715524706600_i1551-6776-17-2-189-b13","article-title":"Cordarone intravenous [package insert]","year":"2001"},{"key":"2020102715524706600_i1551-6776-17-2-189-b14","article-title":"Testing Status of Agents at NTP","author":"US Dept of Health and Human Services, National Toxicity Program","year":"2012"},{"issue":"10","key":"2020102715524706600_i1551-6776-17-2-189-b15","first-page":"2918","article-title":"Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice","volume":"5","author":"van Tellingen","year":"1999","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2020102715524706600_i1551-6776-17-2-189-b16","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.clpt.2003.08.004","article-title":"Disposition of polyoxyethylated excipients in humans: implications for drug safety and formulation approaches","volume":"74","author":"ten Tije","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"2\u20133","key":"2020102715524706600_i1551-6776-17-2-189-b17","first-page":"103","article-title":"Acute and reversible fatty metamorphosis of cultured rat hepatocytes","volume":"47","author":"Yamaki","year":"1997","journal-title":"Pathol Int"},{"issue":"1\u20132","key":"2020102715524706600_i1551-6776-17-2-189-b18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0378-5173(00)00586-X","article-title":"Potential inhibitory effects of formulation ingredients on intestinal chromosome P450","volume":"211","author":"Mountfield","year":"2000","journal-title":"Int J Pharm"},{"issue":"3","key":"2020102715524706600_i1551-6776-17-2-189-b19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1542\/peds.78.3.503","article-title":"Lessons from the E-ferol tragedy","volume":"78","author":"Balistreri","year":"1986","journal-title":"Pediatrics"},{"issue":"6","key":"2020102715524706600_i1551-6776-17-2-189-b20","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/hrt.77.6.583","article-title":"Acute hepatitis complicating parenteral amiodarone does not preclude subsequent oral therapy","volume":"77","author":"James","year":"1997","journal-title":"Heart"},{"key":"2020102715524706600_i1551-6776-17-2-189-b21","article-title":"Cordarone tablets [package insert]","year":"2004"},{"issue":"2","key":"2020102715524706600_i1551-6776-17-2-189-b22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1053\/jhep.2003.50062","article-title":"Cardiac hepatopathy: clinical hemodynamic, and histologic characteristics and correlations","volume":"37","author":"Myers","year":"2003","journal-title":"Hepatology"},{"key":"2020102715524706600_i1551-6776-17-2-189-b23","article-title":"Drugs@FDA: FDA Approved Drug Products","author":"US Food and Drug Administration","year":"2012"}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/17\/2\/189\/1784367\/1551-6776-17_2_189.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/17\/2\/189\/1784367\/1551-6776-17_2_189.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T18:40:57Z","timestamp":1738780857000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/17\/2\/article-p189.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,1]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,10,1]]}},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-17.2.189","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10,1]]}}}